Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Hall

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
BMJ Open|January 1, 2021
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidanceShaista Hafeez, Amanda Webster, Vibeke N Hansen, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
JNCI Cancer Spectrum|October 3, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess responseChris Parker, Nina Tunariu, Holly Tovey, et al.
European Urology Oncology|September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP TrialJames M Wilson, David P Dearnaley, Isabel Syndikus, et al.
Radiology|November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot StudyRaquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
Ebiomedicine|February 22, 2024
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trialTim A D Smith, Catharine M L West, Nuradh Joseph, et al.
The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.
The Lancet. Oncology|January 18, 2011
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialChristopher M Nutting, James P Morden, Kevin J Harrington, et al.
Clinical and Translational Radiation Oncology|October 14, 2022
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentationJulia Murray, Clare Cruickshank, Thomas Bird, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
BMJ Open|January 1, 2021
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidanceShaista Hafeez, Amanda Webster, Vibeke N Hansen, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
JNCI Cancer Spectrum|October 3, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess responseChris Parker, Nina Tunariu, Holly Tovey, et al.
European Urology Oncology|September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP TrialJames M Wilson, David P Dearnaley, Isabel Syndikus, et al.
Radiology|November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot StudyRaquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
Ebiomedicine|February 22, 2024
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trialTim A D Smith, Catharine M L West, Nuradh Joseph, et al.
The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.
The Lancet. Oncology|January 18, 2011
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialChristopher M Nutting, James P Morden, Kevin J Harrington, et al.
Clinical and Translational Radiation Oncology|October 14, 2022
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentationJulia Murray, Clare Cruickshank, Thomas Bird, et al.
Pageof 23